61704-30-1

Usage

Uses

Used in Pharmaceutical Industry:
6-(4-CHLOROPHENYL)-2-PYRIDINECARBOXALDE& is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activity. It has been studied as an inhibitor of certain enzymes, which can contribute to the development of new drugs targeting specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 6-(4-CHLOROPHENYL)-2-PYRIDINECARBOXALDE& serves as an intermediate in the production of agrochemicals, potentially enhancing crop protection and management through its incorporation into new compounds with pesticidal properties.
Used in Antitumor Research:
6-(4-CHLOROPHENYL)-2-PYRIDINECARBOXALDE& is used as a potential antitumor agent in research settings. Its biological activity is being explored for its capacity to inhibit the growth of cancer cells, offering a promising avenue for the development of novel anticancer therapies.
Used in Research and Development:
6-(4-CHLOROPHENYL)-2-PYRIDINECARBOXALDE& is also utilized in the research and development of new chemical compounds and materials, where its unique structure and properties may contribute to the creation of innovative products across various industries.

InChI:InChI=1/C12H8ClNO/c13-10-6-4-9(5-7-10)12-3-1-2-11(8-15)14-12/h1-8H

Upstream product

• 34160-40-2 6-bromo-2-pyridinecarbaldehyde 
• 1679-18-1 4-Chlorophenylboronic acid 

Downstream Products

• 1384182-24-4 1-[6-(4-chlorophenyl)pyridin-2-yl]-N-[2-(methylthio)phenyl]methanimine 
• 1620096-67-4 C₁₃H₈ClF₂N 
• 1620096-10-7 2-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)pyridine 

Relevant academic research and scientific papers

“TPG-lite”: A new, simplified “designer” surfactant for general use in synthesis under micellar catalysis conditions in recyclable water

Using the oxidized, carboxylic acid-containing form of MPEG-750, esterification with racemic vitamin E affords a new surfactant (TPG-lite) that functions as an enabling, nanoreactor-forming amphiphile for use in many types of important reactions in synthesis. The presence of a single ester bond is suggestive of simplified treatment as a component of (eventual) reaction waste water, after recycling. Many types of reactions, including aminations, Suzuki-Miyaura, SNAr, and several others are compared directly with TPGS-750-M, leading to the conclusion that TPG-lite can function as an equivalent nanomicelle-forming surfactant in water. Prima facie evidence amassed via DLS and cryo-TEM analyses support these experimental observations. In silico evaluations of the aquatic toxicity and carcinogenicity of TPG-lite indicate that it is safe to use.

Chemoselective Reductive Aminations in Aqueous Nanoreactors Using Parts per Million Level Pd/C Catalysis

Condensation in recyclable water between aldehydes or ketones and amines occurs smoothly within the hydrophobic cores of nanomicelles, resulting in imine formation that is subject to subsequent reduction leading, overall, to reductive amination. This micellar technology enables the synthesis of several types of pharmaceuticals, a new procedure that relies on only 2000 ppm (0.20 mol %) palladium from commercially available Pd/C. A broad range of substrates can be used under mild conditions, leading to high chemical yields of the desired secondary and tertiary amines.

A new,: Substituted palladacycle for ppm level Pd-catalyzed Suzuki-Miyaura cross couplings in water

A newly engineered palladacycle that contains substituents on the biphenyl rings along with the ligand HandaPhos is especially well-matched to an aqueous micellar medium, enabling valued Suzuki-Miyaura couplings to be run not only in water under mild conditions, but at 300 ppm of Pd catalyst. This general methodology has been applied to several targets in the pharmaceutical area. Multiple recyclings of the aqueous reaction mixture involving both the same as well as different coupling partners is demonstrated. Low temperature microscopy (cryo-TEM) indicates the nature and size of the particles acting as nanoreactors. Importantly, given the low loadings of Pd invested per reaction, ICP-MS analyses of residual palladium in the products shows levels to be expected that are well within FDA allowable limits.

Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations

Protein arginine methyltransferase 5 (PRMT5) is an important protein arginine methyltransferase that catalyzes the symmetric dimethylation of arginine resides on histones or non-histone substrate proteins. It has been thought as a promising target for many diseases, particularly cancer. Despite the potential applications of PRMT5 inhibitors in cancer treatment, very few of PRMT5i have been publicly reported. In this investigation, virtual screening and structure–activity relationship studies were carried out to discover novel PRMT5i, which finally led to the identification of a number of new PRMT5i. The most active compound, P5i-6, exhibited a considerable inhibitory potency against PRMT5 with an IC50 value of 0.57?μm, and a high selectivity for PRMT5 against other tested PRMTs. It displayed a very good antiviability activity against two colorectal cancer cell lines, HT-29 and DLD-1, and one hepatic cancer cell line, HepG2, in a sensitivity assay against 36 different cancer cell lines. Western blot assays indicated that P5i-6 selectively inhibited the symmetric dimethylations of H4R3 and H3R8 in DLD-1 cells. Overall, P5i-6 could be used as a chemical probe to investigate new functions of PRMT5 in biology and also served as a good lead compound for the development of new PRMT5-targeting therapeutic agents.